Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Västra Hamnen Market Focus: Xintela: Taking position for the next phase

Xintela

• Encouraging interim results with XSTEM OA
• EQGen licensing deal signed regarding EQSTEM
• Our fair value amounts to SEK 1.49 per share

During the spring Xintela announced positive interim data from its phase I/IIa study with XSTEM in knee ostoearthritis. The company also signed a license and collaboration agreement wtih EQGen Biomedical regarding EQSTEM. Despite the advances, Xintela's financial situation remains challenging. The company reported cash holdings of MSEK 6.4 by the end of Q1. Most likely, the company will receive proceeds from the warrant TO3, the last exercise period is ongoing. If fully subscribed, TO3 could add MSEK 11. Xintela is also awaiting the upfront fee of MSEK 1 from EQGen.

Our model suggests a fair value of SEK 1.49 per share. The full report is available here.

About Market Focus


The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://x.com/vhcorp_se)

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.